Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA3 | P07451 | 2/20 | 0.54 |
| ▸ | CA4 | P22748 | 2/20 | 0.54 |
| ▸ | CA6 | P23280 | 2/20 | 0.54 |
| ▸ | CA5A | P35218 | 2/20 | 0.54 |
| ▸ | CA7 | P43166 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.43 |
| ▸ | CDK2 | P24941 | 9/20 | 0.43 |
| ▸ | CDK1 | P06493 | 3/20 | 0.43 |
| ▸ | CDK4 | P11802 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15882463 | 0.87 | CCNE1 (0.44) | CA12CA1CA2CA3CA4 | |
| SCHEMBL14419937 | 0.83 | FFAR2 (0.52) | CA12CA1CA2CA3CA4 | |
| SCHEMBL4860224 | 0.83 | CCNE1 (0.44) | CA12CA1CA2CA3CA4 | |
| SCHEMBL6078335 | 0.82 | CA2 (0.53) | CA12CA1CA2CA3CA4 | |
| SCHEMBL540577 | 0.82 | CCNE1 (0.43) | CA12CA1CA2CA3CA4 | |
| Hydrochloric Acid SCHEMBL28108629 | 0.82 | CCNE1 (0.43) | CA12CA1CA2CA3CA4 | |
| SCHEMBL16731877 | 0.81 | CCNE1 (0.49) | CCNE1CDK2CDK1CDK4LMNA | |
| SCHEMBL10233482 | 0.79 | OGA (0.45) | CA12CA1CA2CA3CA4 | |
| SCHEMBL1939387 | 0.79 | CCNE1 (0.43) | CA12CA1CA2CA3CA4 | |
| SCHEMBL27715609 | 0.78 | S1PR1 (0.45) | CA12CA1CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | CA12 4462/4885CA1 4177/4885CA2 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.